A licensing deal with Sarepta Therapeutics (Nasdaq: SRPT) could be worth over $400 million to Lund-based enzyme specialist Hansa Biopharma (STO: HNSA).
The Swedish firm, which is working on immunomodulatory enzyme technology for rare IgG mediated diseases, will receive $10 million upfront and up to $397 million in milestones should all go well.
Sarepta will receive an exclusive, global license to develop and promote Idefirix (imlifidase) as a pre-treatment to enable Sarepta gene therapy in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze